Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV-971 phase 3 trial in mild to moderate Alzheimer's disease
CTR20210187Phase 3Suspended
- Sponsor
- Green Valley
- Start
- Aug 2021
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sodium oligomannate in Alzheimer's disease (AD), sponsored by Green Valley. Started Aug 2021; status: suspended.
02
Drugs
sodium oligomannate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20210187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210187.